Oxford Nanopore Technologies plc Stock

Equities

ONT

GB00BP6S8Z30

Advanced Medical Equipment & Technology

Market Closed - London S.E. 11:35:03 2024-05-31 am EDT 5-day change 1st Jan Change
107.3 GBX +2.00% Intraday chart for Oxford Nanopore Technologies plc -2.72% -48.46%
Sales 2024 * 188M 240M Sales 2025 * 242M 308M Capitalization 926M 1.18B
Net income 2024 * -150M -191M Net income 2025 * -133M -169M EV / Sales 2024 * 3.26 x
Net cash position 2024 * 311M 396M Net cash position 2025 * 197M 251M EV / Sales 2025 * 3.01 x
P/E ratio 2024 *
-6.28 x
P/E ratio 2025 *
-7.24 x
Employees 1,238
Yield 2024 *
-
Yield 2025 *
-
Free-Float 70.12%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.00%
1 week-2.72%
1 month+9.10%
3 months-19.32%
6 months-44.58%
Current year-48.46%
More quotes
1 week
103.70
Extreme 103.7
114.60
1 month
100.00
Extreme 100
117.00
Current year
91.24
Extreme 91.243
212.59
1 year
91.24
Extreme 91.243
279.00
3 years
91.24
Extreme 91.243
736.00
5 years
91.24
Extreme 91.243
736.00
10 years
91.24
Extreme 91.243
736.00
More quotes
Managers TitleAgeSince
Founder - 04-12-31
Founder - 04-12-31
Director of Finance/CFO 42 Jan. 21
Members of the board TitleAgeSince
Director/Board Member 66 21-06-23
Director/Board Member 58 Dec. 18
Chairman 59 22-07-31
More insiders
Date Price Change Volume
24-05-31 107.3 +2.00% 1,864,299
24-05-30 105.2 +0.10% 638,375
24-05-29 105.1 -4.28% 1,160,253
24-05-28 109.8 -0.45% 1,155,258
24-05-24 110.3 -0.72% 1,649,854

Delayed Quote London S.E., May 31, 2024 at 11:35 am EDT

More quotes
Oxford Nanopore Technologies plc is engaged in the generation of molecular sensing technology based on nanopores. The Company has developed a deoxyribonucleic (DNA)/ ribonucleic acid (RNA) sequencing technology. The Company’s segments include Life Science Research Tools, which offers products and services for research use, and COVID Testing, which provides products for SAR-Cov-2 testing. Its sequencing technology offers real-time analysis, in fully scalable formats from pocket to population scale, that can analyze native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths. Its products include MinION, GridION, PromethION, Flongle and others. MinION is a real-time device for DNA and RNA sequencing. GridION is a benchtop device designed to run and analyze up to five MinION or Flongle Flow Cells. Flongle is an adapter for MinION or GridION that enables direct, real-time DNA sequencing, or cDNA sequencing on smaller, single-use flow cells.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
1.073 GBP
Average target price
1.98 GBP
Spread / Average Target
+84.53%
Consensus